Al-Najashi and Y-Innovations back $500m Saudi biotech push

Published: 2026-07-11T13:06:55.000Z

Saudi Arabia has attached half a billion dollars to a simple ambition, which is to stop importing so much of its medicine and start making it at home. A partnership pairs a Saudi healthcare investor with Boston's Y-Innovations in a $500 million push to localize biotechnology.

Saudi Arabia has attached half a billion dollars to a simple ambition, which is to stop importing so much of its medicine and start making it at home. A partnership announced on the sidelines of the BMG Economic Forum at the London Stock Exchange pairs the Saudi healthcare investor connected to Dr Ibrahim Alnajashi, reported variously as Al-Najashi Holding and the fintech firm Seha Invest, with the Boston-based Y-Innovations, in a deal worth 500 million dollars aimed squarely at localizing the biotechnology industry inside the Kingdom. The two sides have set up a dedicated investment platform designed to attract global companies while nurturing homegrown ones. The plan is more concrete than most memorandums of this kind. Over the next five years, the platform intends to attract and localize around 25 companies across fields including advanced cell therapy, medical devices, artificial intelligence and vaccine manufacturing, with a particular emphasis on bringing vaccine development and production onto Saudi soil. Alnajashi framed the goal as combining international innovation with local investment and execution, so that breakthroughs end up as products used in Saudi hospitals rather than research papers. Megan Yung, group chief executive of Y-Innovations, put the emphasis on people, noting the partnership is as much about training a specialized local workforce as it is about relocating technology. The logic behind the spending is rooted in a vulnerability the pandemic exposed. Saudi Arabia remains heavily dependent on imported pharmaceuticals and biologics, an uncomfortable position for a country with a high prevalence of diabetes, cardiovascular disease and inherited disorders, and one it decided to confront through the National Biotechnology Strategy launched in 2024. That strategy rests on four pillars, covering vaccines, biomanufacturing, genomics and plant optimization, and it carries hard targets, aiming for the sector to contribute 3 per cent of non-oil GDP by 2040, an impact valued at nearly 35 billion dollars. The Alnajashi and Y-Innovations tie-up slots neatly into that framework, adding private capital to a push the Public Investment Fund is already backing through vehicles like the manufacturer Lifera. The regional stakes are considerable, since every Gulf state learned the same supply-chain lesson at once and each now wants to be the region's life-sciences hub. Saudi Arabia's advantage lies in scale and in a genomics program built around a population with a distinctive genetic profile, which makes locally developed therapies commercially and clinically valuable. The UAE is pursuing comparable ambitions, and both are competing for the same scarce pool of international biotech firms and specialized talent. What this deal signals is that the Kingdom increasingly intends to buy its way up the value chain, using capital to import capability it cannot yet grow fast enough on its own.